Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2023

  1. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2021

  1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

2020

  1. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11